OBJECTIVE: Lung tissue deposition of intravenous ceftazidime administered either continuously or intermittently was compared in ventilated piglets with experimental bronchopneumonia. DESIGN: Prospective experimental study ANIMALS: Eighteen anesthetized and ventilated piglets INTERVENTIONS: Bronchopneumonia was produced by the intrabronchial inoculation of Pseudomonas aeruginosa characterized by an impaired sensitivity to ceftazidime (MIC 16 mg/l). Ceftazidime was administered either through a continuous infusion of 90 mg/kg per 24 h after a bolus of 30 mg/kg or by an intermittent infusion of 30 mg/kg per 8 h. MEASUREMENTS AND RESULTS: Piglets were killed 24 h after the initiation of continuous ceftazidime (n = 6), and 1 h (peak, n = 6) and 8 h (trough, n = 6) after the third dose following intermittent administration. Lung tissue concentrations of ceftazidime, measured by HPLC, and lung bacterial burden were assessed on multiple postmortem lung specimens. During continuous administration ceftazidime lung tissue concentrations were 9.7 +/- 3.8 microg/g. Following intermittent administration peak and trough lung tissue concentrations were, respectively, 7.1 +/- 2.4 microg/g and 0.6 +/- 1 microg/g. Lung bacterial burden was different after continuous and intermittent administration (median 7.10(3) vs. 4.10(2) cfu/g). CONCLUSIONS: Continuous infusion of ceftazidime maintained higher tissue concentrations than intermittent administration.
OBJECTIVE: Lung tissue deposition of intravenous ceftazidime administered either continuously or intermittently was compared in ventilated piglets with experimental bronchopneumonia. DESIGN: Prospective experimental study ANIMALS: Eighteen anesthetized and ventilated piglets INTERVENTIONS:Bronchopneumonia was produced by the intrabronchial inoculation of Pseudomonas aeruginosa characterized by an impaired sensitivity to ceftazidime (MIC 16 mg/l). Ceftazidime was administered either through a continuous infusion of 90 mg/kg per 24 h after a bolus of 30 mg/kg or by an intermittent infusion of 30 mg/kg per 8 h. MEASUREMENTS AND RESULTS: Piglets were killed 24 h after the initiation of continuous ceftazidime (n = 6), and 1 h (peak, n = 6) and 8 h (trough, n = 6) after the third dose following intermittent administration. Lung tissue concentrations of ceftazidime, measured by HPLC, and lung bacterial burden were assessed on multiple postmortem lung specimens. During continuous administration ceftazidime lung tissue concentrations were 9.7 +/- 3.8 microg/g. Following intermittent administration peak and trough lung tissue concentrations were, respectively, 7.1 +/- 2.4 microg/g and 0.6 +/- 1 microg/g. Lung bacterial burden was different after continuous and intermittent administration (median 7.10(3) vs. 4.10(2) cfu/g). CONCLUSIONS: Continuous infusion of ceftazidime maintained higher tissue concentrations than intermittent administration.
Authors: M A Robaux; L Dube; J Caillon; D Bugnon; M F Kergueris; D Navas; P Le Conte; D Baron; G Potel Journal: J Antimicrob Chemother Date: 2001-05 Impact factor: 5.790
Authors: R Roosendaal; I A Bakker-Woudenberg; M van den Berghe-van Raffe; J C Vink-van den Berg; B M Michel Journal: Eur J Clin Microbiol Infect Dis Date: 1989-10 Impact factor: 3.267
Authors: J J Rouby; E Martin De Lassale; P Poete; M H Nicolas; L Bodin; V Jarlier; Y Le Charpentier; J Grosset; P Viars Journal: Am Rev Respir Dis Date: 1992-10
Authors: Peter Andrews; Elie Azoulay; Massimo Antonelli; Laurent Brochard; Christian Brun-Buisson; Daniel De Backer; Geoffrey Dobb; Jean-Yves Fagon; Herwig Gerlach; Johan Groeneveld; Duncan Macrae; Jordi Mancebo; Philipp Metnitz; Stefano Nava; Jerôme Pugin; Michael Pinsky; Peter Radermacher; Christian Richard Journal: Intensive Care Med Date: 2006-12-19 Impact factor: 17.440
Authors: Marc O Maybauer; Dirk M Maybauer; John F Fraser; Lillian D Traber; Martin Westphal; Robert A Cox; Ruksana Huda; Yoshimitsu Y Nakano; Perenlei Enkhbaatar; Hal K Hawkins; David N Herndon; Daniel L Traber Journal: Intensive Care Med Date: 2007-05-15 Impact factor: 17.440